Sage Therapeutics Archives -

Shares in Praxis Precision Medicines were in freefall today after the company’s efforts to develop a new therapy

Praxis wields the axe as lead depression drug fails

https://pharmaphorum.com/news/praxis-wields-the-axe-as-lead-depression-drug-fails/

Last year, the first phase 3 trial of Sage Therapeutics and Biogen’s antidepressant hopeful zuranolone hit its efficacy

Sage, Biogen’s zuranolone looks approvable, but will it sell?

https://pharmaphorum.com/news/sage-biogens-zuranolone-looks-approvable-but-will-it-sell/

The renaissance of Biogen and Sage Therapeutics antidepressant zuranolone continues, with the companies indicating they now plan to

Biogen, Sage prep 2022 filing for depression drug zuranolone

https://pharmaphorum.com/news/biogen-sage-prep-2022-filing-for-depression-drug-zuranolone/

Sage Therapeutics and Biogen’s antidepressant candidate zuranolone has hit its objectives in a phase 3 trial, but a

Sage/Biogen’s zuranolone works in depression, but maybe not enough

https://pharmaphorum.com/news/sage-biogens-zuranolone-works-in-depression-but-maybe-not-enough/

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore

Biogen bulks up pipeline with Sage drugs in $3bn deal

https://pharmaphorum.com/news/biogen-bulks-up-pipeline-with-sage-drugs-in-3bn-deal/

One of the biggest headline-grabbers at the 2019 JP Morgan Healthcare conference this week was Sage Therapeutics unveiling

R&D roundup – Sage impresses at JP Morgan

https://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-sage-impresses-at-jp-morgan/

Sage Therapeutics